Novo Nordisk is investing DKK 400 million ($59.4 million) in a 500-square meter extension of its insulin production plant in Kalundborg, Denmark.

Established in 1969, the Kalundborg production site today covers a total area of 1.1 million square meters. With its 3,400 employees, Novo Nordisk Kalundborg is a key part of Novo Nordisk’s global production and produces 50% of the world’s insulin as well as a range of biopharmaceutical products, according to Novo Nordisk.

The company broke ground on the expansion which is expected to be completed at the end of 2018.

Source: Novo Nordisk